Related Experiment Video
Updated: Apr 26, 2026
08:14
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
7.3K
PCSK9 and lipid lowering drugs
Yuan-Lin Guo1, Wei Zhang2, Jian-Jun Li1
1Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China.
Summary
Proprotein convertase subtilisin/kexin type 9 (PCSK9) influences cholesterol levels and cardiovascular risk. This review examines how lipid-lowering drugs affect PCSK9, impacting cholesterol control strategies.
Area of Science:
- Biochemistry and Pharmacology
- Cardiovascular Medicine
- Metabolic Disorders
Background:
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of cholesterol metabolism.
- PCSK9 levels significantly impact low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk.
- Understanding factors influencing PCSK9 concentration is crucial for pharmacological interventions.
Purpose of the Study:
- To review the impact of lipid-lowering drugs on circulating PCSK9 concentrations.
- To discuss the clinical implications of these drug-induced PCSK9 changes.
- To inform current cholesterol control strategies.
Main Methods:
- Literature review of experimental and clinical studies.
- Analysis of data on PCSK9 expression and lipid-lowering therapies.
- Synthesis of findings related to cardiovascular risk and atherosclerosis.
Main Results:
- Lipid-lowering drugs demonstrably alter circulating PCSK9 levels.
- Changes in PCSK9 induced by these drugs have direct clinical relevance.
- PCSK9 modulation is a significant factor in managing cholesterol and cardiovascular health.
Conclusions:
- Lipid-lowering drugs play a critical role in modulating PCSK9.
- Understanding PCSK9 dynamics is essential for optimizing lipid management.
- This knowledge aids in refining therapeutic strategies for cholesterol control and reducing cardiovascular events.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:29Pharmacogenomics: Identification of New Drug Targets
119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
01:26Coronary Artery Disease IV: Preventive Measures
888
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
888
01:26Atherosclerosis III: Management
719
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
719
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
839
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
839
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K